Q3 EPS Forecast for Sensei Biotherapeutics Raised by Analyst

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Sensei Biotherapeutics in a report released on Wednesday, August 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.58) for the quarter, up from their previous forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Sensei Biotherapeutics’ current full-year earnings is ($15.23) per share. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($13.54) EPS, Q1 2027 earnings at ($0.61) EPS, Q2 2027 earnings at ($0.63) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.75) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($2.37) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($2.54) EPS.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter.

A number of other research firms have also recently issued reports on FTH. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. JonesTrading initiated coverage on Sensei Biotherapeutics in a report on Tuesday. They set a “buy” rating and a $55.00 price objective on the stock. Oppenheimer started coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price for the company. Citizens Jmp started coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $51.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Trading Down 0.4%

FTH opened at $24.48 on Friday. Sensei Biotherapeutics has a 52 week low of $7.20 and a 52 week high of $37.90. The firm has a market capitalization of $32.85 million, a P/E ratio of -0.17 and a beta of -0.25.

Insider Activity

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of hedge funds have recently modified their holdings of FTH. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics during the first quarter worth about $4,188,000. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics during the 1st quarter valued at about $22,758,000. Bank of America Corp DE raised its position in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across every reported period. The firm reduced its expected losses for Q3 2026 to $0.58 per share from $0.69, FY2026 to $13.54 from $16.61, and FY2027 to $2.68 from $3.72. It also improved estimates for FY2028, FY2029 and FY2030, suggesting the analyst expects Sensei Biotherapeutics’ financial performance to improve more quickly than previously projected.
• Positive Sentiment: The revisions also covered 2027 quarterly results, with projected losses narrowed to $0.61 per share in Q1, $0.63 in Q2, $0.66 in Q3 and $0.75 in Q4. Although the company remains unprofitable, the direction of the revisions is favorable and may strengthen investor confidence in its longer-term outlook.
• Neutral Sentiment: JonesTrading began coverage of Sensei Biotherapeutics. The article does not disclose a rating, price target or detailed investment thesis, so the immediate effect of the new coverage is uncertain. JonesTrading Begins Coverage on Sensei Biotherapeutics
• Negative Sentiment: Despite the improved forecasts, HC Wainwright still expects substantial losses, while the broader current-year consensus calls for a $15.23-per-share loss. Sensei Biotherapeutics’ latest reported quarterly EPS was also negative at $131.45, highlighting the company’s continuing profitability and execution risks.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.